派林生物(000403)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

000403 派林生物

已收盘 07-14 15:00:00

{"stockData":{"symbol":"000403","market":"SZ","secType":"STK","nameCN":"派林生物","latestPrice":17.88,"timestamp":1752476592000,"preClose":17.84,"halted":0,"volume":11390172,"delay":0,"changeRate":0.0022,"floatShares":941000000,"shares":950000000,"eps":0.7497,"marketStatus":"已收盘","change":0.04,"latestTime":"07-14 15:00:00","open":17.83,"high":18.13,"low":17.78,"amount":204000000,"amplitude":0.0196,"askPrice":17.88,"askSize":97,"bidPrice":17.87,"bidSize":538,"shortable":0,"etf":0,"ttmEps":0.7497,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1752543000000},"marketStatusCode":5,"adr":0,"adjPreClose":17.84,"symbolType":"stock","openAndCloseTimeList":[[1752456600000,1752463800000],[1752469200000,1752476400000]],"highLimit":19.62,"lowLimit":16.06,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":950397386,"isCdr":false,"pbRate":2.12,"roa":"--","peRate":23.84954,"roe":"1.12%","epsLYR":1.02,"committee":0.605653,"marketValue":16993000000,"turnoverRate":0.0121,"status":0,"floatMarketCap":16820000000},"requestUrl":"/m/hq/s/000403","defaultTab":"news","newsList":[{"id":"2551074911","title":"每周股票复盘：派林生物（000403）部分募集资金专户完成销户","url":"https://stock-news.laohu8.com/highlight/detail?id=2551074911","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2551074911?lang=zh_cn&edition=full","pubTime":"2025-07-13 06:13","pubTimestamp":1752358389,"startTime":"0","endTime":"0","summary":"截至2025年7月11日收盘，派林生物报收于17.84元，较上周的18.04元下跌1.11%。公司设立了募集资金专项账户，并与国泰海通证券、开户银行、项目实施子公司签署了募集资金监管协议。公司办理了相关募集资金专项账户的销户手续，并将该事项及时通知保荐机构和保荐代表人。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025071300001125.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0071","000403","BK0239"],"gpt_icon":0},{"id":"2550640686","title":"派林生物股价微跌0.17% 控股股东拟转让股份引关注","url":"https://stock-news.laohu8.com/highlight/detail?id=2550640686","media":"金融界","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2550640686?lang=zh_cn&edition=full","pubTime":"2025-07-10 20:06","pubTimestamp":1752149189,"startTime":"0","endTime":"0","summary":"截至2025年7月10日15时，派林生物股价报17.76元，较前一交易日下跌0.03元，跌幅0.17%。公司此前公告显示，控股股东胜帮英豪计划将其持有的21.03%股份转让给中国生物，若交易完成，公司实际控制人将由陕西省国资委变更为国药集团。此次股权转让价格涉及本金及年化9%的利息，引发市场对交易条款的关注。资金方面，派林生物7月10日主力资金净流出1111.69万元，占流通市值比例为0.07%。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.jrj.com.cn/2025/07/10200651611753.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["000403","BK0239","BK0071"],"gpt_icon":0},{"id":"2548840124","title":"血液制品概念盘中拉升，派林生物涨2.36%","url":"https://stock-news.laohu8.com/highlight/detail?id=2548840124","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2548840124?lang=zh_cn&edition=full","pubTime":"2025-07-03 10:02","pubTimestamp":1751508147,"startTime":"0","endTime":"0","summary":"07月03日，血液制品概念盘中拉升，截至10点02分，血液制品概念整体指数上涨1.04%，报819.410点。从个股上来看，该概念的成分股中，派林生物涨2.36%，赛伦生物、天坛生物、卫光生物涨幅居前。从资金上来看，截止发稿，血液制品概念概念主力净流入为2290.52万，其中天坛生物受到资金热捧，主力净流入2267.14万；拉长时间线来看，该板块近20日主力资金净流入-9.40亿。（以上内容为腾讯自选股基于公开消息，由程序或算法智能生成，仅作为用户看盘参考，不作为投资建议或交易依据。股市有风险，请谨慎决策。）","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250703100227a4cc39b4&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250703100227a4cc39b4&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0239","BK0168","600161","BK0071","BK0185","BK0046","000403","BK0010","BK0082","BK0028","BK0188"],"gpt_icon":0},{"id":"2543637897","title":"每周股票复盘：派林生物（000403）控股股东拟变更，股票复牌","url":"https://stock-news.laohu8.com/highlight/detail?id=2543637897","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2543637897?lang=zh_cn&edition=full","pubTime":"2025-06-14 03:46","pubTimestamp":1749843972,"startTime":"0","endTime":"0","summary":"截至2025年6月13日收盘，派林生物报收于18.23元，较上周的16.96元上涨7.49%。若交易完成，公司控股股东将由胜帮英豪变更为中国生物，实际控制人将由陕西省国资委变更为中国医药集团有限公司。中国生物将开展尽职调查工作，尽职调查完成后，各方将确定是否签署正式协议，交易存在后续协议签署时间待定、未能签署及交易无法达成的风险。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025061400008104.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["000403","BK0239","BK0071"],"gpt_icon":0},{"id":"2542569529","title":"生物制品行业盘中拉升，派林生物涨停","url":"https://stock-news.laohu8.com/highlight/detail?id=2542569529","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2542569529?lang=zh_cn&edition=full","pubTime":"2025-06-12 13:05","pubTimestamp":1749704736,"startTime":"0","endTime":"0","summary":"06月12日，生物制品行业盘中拉升，截至13点05分，生物制品行业整体指数上涨1.01%，报6331.120点。从个股上来看，该行业的成分股中，派林生物涨停，百普赛斯、荣昌生物2只股涨幅超过5%。从资金上来看，截止发稿，生物制品行业主力净流入为-1722.24万，其中派林生物受到资金热捧，主力净流入9737.29万；拉长时间线来看，该板块近20日主力资金净流入-5.54亿。（以上内容为腾讯自选股基于公开消息，由程序或算法智能生成，仅作为用户看盘参考，不作为投资建议或交易依据。股市有风险，请谨慎决策。）","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250612130536a7049930&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250612130536a7049930&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU1064130708.USD","LU2148510915.USD","LU2488822045.USD","BK0071","LU1064131003.USD","000403","688331","BK0239"],"gpt_icon":0},{"id":"2542381378","title":"派林生物最新公告：中国生物受让21.03%公司股份 股票复牌","url":"https://stock-news.laohu8.com/highlight/detail?id=2542381378","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2542381378?lang=zh_cn&edition=full","pubTime":"2025-06-09 19:39","pubTimestamp":1749469187,"startTime":"0","endTime":"0","summary":"派林生物(000403.SZ)公告称，公司股票自2025年6月10日开市起复牌。公司控股股东胜帮英豪与中国生物签署了《收购框架协议》，拟将所持公司21.03%股份转让给中国生物。若交易顺利完成，公司控股股东将由胜帮英豪变更为中国生物，实际控制人将由陕西省国资委变更为中国医药集团有限公司。但该事项仍存在不确定性，包括后续协议签署时间待定、未能签署及交易无法达成的风险，以及是否能最终实施完成及实施结果的不确定性。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025060900027751.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["000403","BK0071","BK0239"],"gpt_icon":0},{"id":"2541892953","title":"每周股票复盘：派林生物（000403）控制权变更事项停牌，董事会审议通过整改报告","url":"https://stock-news.laohu8.com/highlight/detail?id=2541892953","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2541892953?lang=zh_cn&edition=full","pubTime":"2025-06-07 09:50","pubTimestamp":1749261023,"startTime":"0","endTime":"0","summary":"截至2025年6月5日收盘，派林生物报收于16.96元，较上周的22.13元下跌23.36%。表决结果为13票同意、0票反对、0票弃权。关于筹划控制权变更事项的停牌公告：公司股票自2025年6月6日开市起停牌，预计停牌时间不超过2个交易日。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025060700009793.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["000403","BK0239","BK0071"],"gpt_icon":0},{"id":"2541027480","title":"派林生物(000403.SZ)：控制权或将发生变更 6月6日起停牌","url":"https://stock-news.laohu8.com/highlight/detail?id=2541027480","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2541027480?lang=zh_cn&edition=full","pubTime":"2025-06-05 19:52","pubTimestamp":1749124347,"startTime":"0","endTime":"0","summary":"智通财经APP讯，派林生物(000403.SZ)公告，公司近日收到控股股东共青城胜帮英豪投资合伙企业(有限合伙)的通知，其正在筹划涉及公司控制权变更的事项。公司股票自2025年6月6日开市起停牌，预计停牌时间不超过2个交易日。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1301868.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["000403","BK0071","BK0239"],"gpt_icon":0},{"id":"2541193013","title":"派林生物：公司近年持续强化全面预算管理，加强过程战略督导，加快采浆、生产和销售业务链衔接和计划执行，以不断提升经营效率","url":"https://stock-news.laohu8.com/highlight/detail?id=2541193013","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2541193013?lang=zh_cn&edition=full","pubTime":"2025-06-05 09:12","pubTimestamp":1749085955,"startTime":"0","endTime":"0","summary":"证券之星消息，派林生物(000403)06月04日在投资者关系平台上答复投资者关心的问题。投资者提问：尊敬的董秘，您好！贵公司的存货周转天数优于同行业的竞争对手，特别是库存商品的库存周转天数很优秀，请问贵公司在优化存货管理、提升存货周转效率，产成品库存控制等方面采取了哪些具体措施？谢谢！派林生物回复：尊敬的投资者，您好！公司近年持续强化全面预算管理，加强过程战略督导，加快采浆、生产和销售业务链衔接和计划执行，以不断提升经营效率。谢谢！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025060500004147.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0071","BK0239","000403"],"gpt_icon":0},{"id":"2538010332","title":"派林生物(000403.SZ)拟10股转增3股派3.5元 于6月4日除权除息","url":"https://stock-news.laohu8.com/highlight/detail?id=2538010332","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2538010332?lang=zh_cn&edition=full","pubTime":"2025-05-26 19:22","pubTimestamp":1748258531,"startTime":"0","endTime":"0","summary":"智通财经APP讯，派林生物(000403.SZ)公告，公司2024年度利润分配拟：向全体股东每10股派3.5元人民币现金(含税)，同时，以资本公积金向全体股东每10股转增3股。本次权益分派股权登记日为：2025年6月3日，除权除息日为：2025年6月4日。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1297685.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["000403","BK0071","BK0239"],"gpt_icon":0},{"id":"2537954161","title":"每周股票复盘：派林生物（000403）2025年产能提升超3000吨，新产品预计26、27年上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2537954161","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2537954161?lang=zh_cn&edition=full","pubTime":"2025-05-24 11:36","pubTimestamp":1748057772,"startTime":"0","endTime":"0","summary":"截至2025年5月23日收盘，派林生物报收于21.73元，较上周的21.57元上涨0.74%。答：子公司广东双林九因子预计2026年获得上市批文，第四代静丙预计2027年获得上市批文，具体进展以公司信息披露公告为准。答：派斯菲科二期扩能验收后已于2025年3月初正式投产，广东双林产能提升预计于2025年6月投产，扩能后年产能将提升至超3000吨。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025052400011261.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0071","000403"],"gpt_icon":0},{"id":"2537941891","title":"派林生物：5月21日高管左超增持股份合计9700股","url":"https://stock-news.laohu8.com/highlight/detail?id=2537941891","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2537941891?lang=zh_cn&edition=full","pubTime":"2025-05-22 21:01","pubTimestamp":1747918898,"startTime":"0","endTime":"0","summary":"证券之星消息，根据5月22日市场公开信息、上市公司公告及交易所披露数据整理，派林生物最新董监高及相关人员股份变动情况：2025年5月21日公司监事左超共增持公司股份9700.0股，占公司总股本为0.0013%。变动期间公司股价下跌0.23%，5月21日当日收盘报21.84元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025052200035694.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0071","000403","BK0239"],"gpt_icon":0},{"id":"2535388773","title":"派林生物：公司2025年采浆量预计超1600吨","url":"https://stock-news.laohu8.com/highlight/detail?id=2535388773","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2535388773?lang=zh_cn&edition=full","pubTime":"2025-05-16 08:51","pubTimestamp":1747356676,"startTime":"0","endTime":"0","summary":"证券之星消息，派林生物05月15日在投资者关系平台上答复投资者关心的问题。随着智能工厂的扩产今年预计是否有百分之20左右的增长？谢谢派林生物回复：尊敬的投资者，您好！公司2025年采浆量预计超1600吨；公司扩能后年产能将提升至超3,000吨，2025年投浆量预计超1,400吨，2025年投浆量将同比增长超20%，公司利润的目标增长率将维持在两位数以上；吨浆净利润将随着新产品持续增加及经营效率提升等持续提升，具体请您关注公司公告。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025051600005907.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0071","000403","BK0239"],"gpt_icon":0},{"id":"2535220076","title":"派林生物陷内控风波两任董事长遭警示 产能扩建阵痛致首季业绩双降","url":"https://stock-news.laohu8.com/highlight/detail?id=2535220076","media":"立刻财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2535220076?lang=zh_cn&edition=full","pubTime":"2025-05-14 22:05","pubTimestamp":1747231500,"startTime":"0","endTime":"0","summary":"2020年，时任控股股东浙民投对派林生物进行资产重组，通过发行股份的方式收购了黑龙江血制品企业派斯菲科，派斯菲科实控人、董事长付绍兰由此进入派林生物，并在后来被推举为上市公司的董事长，派林生物由此进入高速发展时期。对此，派林生物解释称，业绩下滑主要受全资子公司派斯菲科二期产能扩增停产导致产品供应量同比下降的影响。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/roll/2025-05-14/doc-inewqanu0180891.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0071","BK0239","000403"],"gpt_icon":0},{"id":"2535757407","title":"派林生物：5月12日高管荣先奎、左超、王晔弘增持股份合计1.68万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2535757407","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2535757407?lang=zh_cn&edition=full","pubTime":"2025-05-13 21:01","pubTimestamp":1747141295,"startTime":"0","endTime":"0","summary":"证券之星消息，根据5月13日市场公开信息、上市公司公告及交易所披露数据整理，派林生物最新董监高及相关人员股份变动情况：2025年5月12日公司高管荣先奎、监事左超、高管王晔弘共增持公司股份1.68万股，占公司总股本为0.0024%。变动期间公司股价上涨0.5%，5月12日当日收盘报21.99元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025051300036531.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0071","000403"],"gpt_icon":0},{"id":"2534065407","title":"派林生物(000403.SZ)收到山西证监局行政监管措施决定书","url":"https://stock-news.laohu8.com/highlight/detail?id=2534065407","media":"智通财经","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2534065407?lang=zh_cn&edition=full","pubTime":"2025-05-11 16:40","pubTimestamp":1746952824,"startTime":"0","endTime":"0","summary":"二是公司部分重大事项未进行内幕信息知情人登记，部分内幕信息知情人登记档案不完整。根据《上市公司信息披露管理办法》第五十二条，《上市公司现场检查规则》第二十一条，《上市公司监管指引第5号——上市公司内幕信息知情人登记管理制度》第十六条第三项的规定，山西证监局决定对公司采取责令改正的监督管理措施，并记入证券期货市场诚信档案。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1291727.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","000403","BK0071"],"gpt_icon":0},{"id":"2531345140","title":"派林生物：公司目前已获得超10个县级批文和超5个市级批文","url":"https://stock-news.laohu8.com/highlight/detail?id=2531345140","media":"证券","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2531345140?lang=zh_cn&edition=full","pubTime":"2025-04-30 19:36","pubTimestamp":1746012960,"startTime":"0","endTime":"0","summary":"证券日报网讯派林生物4月30日在互动平台回答投资者提问时表示，公司非常重视新浆站拓展工作，公司目前已获得超10个县级批文和超5个市级批文，2025年度公司将重点推动新浆站拓展，力争实现新浆站突破。\n\n\n\n海量资讯、精准解读，尽在新浪财经APP","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2025-04-30/doc-ineuyanr4634570.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["000403","BK0071","BK0239"],"gpt_icon":0},{"id":"2531724480","title":"【派林生物：2025年投浆量将同比增长超20%】 派林生物在深交所互动平台上表示，公司目前已获得超10个县级批文和超5个市级批文，2025年度公司将重点推动新浆站拓展，力争实现新浆站突破。此外，公司表示，公司2025年一季度经营业绩同比下降主要因为公司下属子公司派斯菲科二期产能扩增停产影响，但产能扩增后2025年投浆量预计超1400吨，2025年投浆量将同比增长超20%，公司利润的目标增长率将维持在两位数以上。","url":"https://stock-news.laohu8.com/highlight/detail?id=2531724480","media":"金融界","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2531724480?lang=zh_cn&edition=full","pubTime":"2025-04-30 11:47","pubTimestamp":1745984844,"startTime":"0","endTime":"0","summary":"派林生物在深交所互动平台上表示，公司目前已获得超10个县级批文和超5个市级批文，2025年度公司将重点推动新浆站拓展，力争实现新浆站突破。此外，公司表示，公司2025年一季度经营业绩同比下降主要因为公司下属子公司派斯菲科二期产能扩增停产影响，但产能扩增后2025年投浆量预计超1400吨，2025年投浆量将同比增长超20%，公司利润的目标增长率将维持在两位数以上。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/04/30114750034331.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK0239","000403","BK0071"],"gpt_icon":0},{"id":"2531734831","title":"派林生物：4月28日高管荣先奎、王晔弘增持股份合计7800股","url":"https://stock-news.laohu8.com/highlight/detail?id=2531734831","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2531734831?lang=zh_cn&edition=full","pubTime":"2025-04-29 21:04","pubTimestamp":1745931870,"startTime":"0","endTime":"0","summary":"证券之星消息，根据4月29日市场公开信息、上市公司公告及交易所披露数据整理，派林生物最新董监高及相关人员股份变动情况：2025年4月28日公司高管荣先奎、高管王晔弘共增持公司股份7800.0股，占公司总股本为0.0011%。变动期间公司股价上涨0.23%，4月28日当日收盘报21.69元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025042900041114.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["000403","BK0071","BK0239"],"gpt_icon":0},{"id":"2530002774","title":"派林生物：4月25日高管荣先奎、赵玉林、王晔弘增持股份合计1.7万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2530002774","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2530002774?lang=zh_cn&edition=full","pubTime":"2025-04-28 21:01","pubTimestamp":1745845280,"startTime":"0","endTime":"0","summary":"证券之星消息，根据4月28日市场公开信息、上市公司公告及交易所披露数据整理，派林生物最新董监高及相关人员股份变动情况：2025年4月25日公司高管荣先奎、董秘赵玉林、高管王晔弘共增持公司股份1.7万股，占公司总股本为0.0023%。变动期间公司股价下跌2.7%，4月25日当日收盘报21.64元。该股最近90天内共有6家机构给出评级，买入评级5家，增持评级1家；过去90天内机构目标均价为24.96。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025042800035369.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","000403","BK0071"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1752521734448,"stockEarnings":[{"period":"1week","weight":-0.0138},{"period":"1month","weight":-0.0192},{"period":"3month","weight":-0.0284},{"period":"6month","weight":0.1033},{"period":"1year","weight":-0.108},{"period":"ytd","weight":0.1174}],"compareEarnings":[{"period":"1week","weight":0.0134},{"period":"1month","weight":0.0422},{"period":"3month","weight":0.0771},{"period":"6month","weight":0.0906},{"period":"1year","weight":0.1846},{"period":"ytd","weight":0.0501}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"派斯双林生物制药股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"29271人(较上一季度增加7.71%)","perCapita":"32137股","listingDate":"1996-06-28","address":"山西省太原市晋源区长兴南街8号阳光城环球金融中心3004室","registeredCapital":"95039万元","survey":"　　派斯双林生物制药股份有限公司的主营业务是血液制品的研究、开发、生产和销售。公司的主要产品是人血白蛋白、静注人免疫球蛋白（pH4）、人免疫球蛋白、乙型肝炎人免疫球蛋白、破伤风人免疫球蛋白、狂犬病人免疫球蛋白、人凝血因子Ⅷ、人凝血酶原复合物、人血白蛋白、静注人免疫球蛋白（pH4）、冻干静注人免疫球蛋白（pH4）、人免疫球蛋白、人纤维蛋白原、乙型肝炎人免疫球蛋白、破伤风人免疫球蛋白、狂犬病人免疫球蛋白、静注乙型肝炎人免疫球蛋白（pH4）。","listedPrice":3.78},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.34.3","shortVersion":"4.34.3","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"派林生物(000403)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供派林生物(000403)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"派林生物,000403,派林生物股票,派林生物股票老虎,派林生物股票老虎国际,派林生物行情,派林生物股票行情,派林生物股价,派林生物股市,派林生物股票价格,派林生物股票交易,派林生物股票购买,派林生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"派林生物(000403)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供派林生物(000403)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}